drugset / Trial / NCT06987500
A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment
Phase 1/2
Recruiting
132 enrolled
Evopoint Biosciences Inc.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to characterize the safety, tolerability, and efficacy of XNW29016 in participants with advanced solid tumors .
Timeline
- Start
- 2025-04-11
- Primary completion
- 2027-02-14
- Completion
- 2027-08-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XNW29016 | Unknown | — | Oral |
Indications
No indication recorded.